Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027
Collaboration combines Samsung Bioepis’ biosimilar expertise with T......
